Appointment booking for Dr. Douglas Amare, MD is currently not available.Dr. Douglas Amare, MD has not yet fully activated their profile on DiabetesIQ.
Dr. Douglas Amare, MD (he/him) is a Nephrologist in Mobile, AL with over 18 years of experience. What is your opinion of Dr. Douglas Amare, MD? Rate this provider below so other people can make informed decision.
Gender
Male
Experience
Over 18 Years of Experience
Languages Spoken
English
Accepted Insurances
Medicare
Payments Received
Many providers receive payments from medical companies such as pharmaceutical companies and medical device companies. These payments can range from small amounts for meals to large consulting fees. We provide this information in order to make healthcare system more transparent. Between 2014 and 2020 Dr. Douglas Amare, MD has received over $4,732 which includes payments from the following companies:
$2,075.93 from Horizon Pharma plc
$477.77 from Otsuka America Pharmaceutical, Inc.
$456.24 from Relypsa, Inc.
$389.06 from OPKO Pharmaceuticals, LLC
$367.74 from Keryx Biopharmaceuticals, Inc.
$182.72 from sanofi-aventis U.S. LLC
$179.02 from Mallinckrodt LLC
$178.03 from AKEBIA THERAPEUTICS INC
$143.23 from Amgen Inc.
$71.84 from Questcor Pharmaceuticals
$60.66 from Bard Peripheral Vascular, Inc.
$39.18 from W. L. Gore & Associates, Inc.
$29.75 from Novartis Pharmaceuticals Corporation
$20.20 from Abbott Laboratories
$18.45 from Mallinckrodt Hospital Products Inc.
$16.78 from Daiichi Sankyo Inc.
$13.27 from GENZYME CORPORATION
$12.25 from AstraZeneca Pharmaceuticals LP
Payments received by Dr. Douglas Amare, MD were from the following categories:
Do you have any questions about your diabetes condition or general questions about diabetes? You can now post those questions in DiabetesIQ Forum and have our diabetes experts answer your questions for FREE! Yes, there is absolutely no catch! - Registration only takes a few seconds and it's FREE. No credit card needed. You can ask any number of diabetes questions, all for FREE! Register today and join the conversation!